Completed PHASE3 INTERVENTIONAL NCT00160628

Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects

Sponsor: UCB Pharma

Conditions Epilepsy, Partial

Interventions Levetiracetam

Updated 6 times since 2017 Last updated: Nov 25, 2013 Started: Mar 31, 2004 Primary completion: Oct 31, 2004 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00160628, this PHASE3 trial focuses on Epilepsy, Partial and remains completed. Sponsored by UCB Pharma, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.